AllianceRx Walgreens Prime named exclusive distributor for HRA Pharma Rare Diseases in the US

AllianceRx Walgreens Prime named exclusive distributor for HRA Pharma Rare Diseases FDA approved prescription drugs Lysodren® and Metopirone® in the United States

Orlando, FL, Morristown, NJ and Chatillon France – Nov. 1, 2020 – HRA Pharma Rare Diseases has named AllianceRx Walgreens Prime – one of the largest specialty and home delivery pharmacies in the United States as the exclusive specialty pharmacy and clinical support provider for two of its rare disease drugs, Lysodren® and Metopirone®. As a result of this agreement, each medication is now available through AllianceRx Walgreens Prime and select Walgreens community-based local specialty pharmacies.

Lysodren® (mitotane) is the only FDA approved drug to treat inoperable, functional or non-functional adrenocortical carcinoma, a rare cancer of the adrenal glands. Metopirone® (metyrapone) is used as a diagnostic test for adrenocorticotropic hormone (ACTH) insufficiency and in the diagnosis of ACTHdependent Cushing’s syndrome. ACTH is a hormone produced in the pituitary gland in the brain.

“We are very excited to be the exclusive pharmacy to dispense these medicines,” says Tracey James, senior vice president of pharmacy services at AllianceRx Walgreens Prime. “HRA Pharma Rare Diseases recognizes that leveraging our extensive network means more patients with these rare conditions will have access to these essential medicines. Combined with our ability to offer support throughout their treatment, HRA Pharma Rare Diseases and AllianceRx Walgreens Prime share the same goal of providing the best possible outcomes for these patients.”

Evelina Paberze, Chief Operating Officer of HRA Pharma Rare Diseases, says, “At HRA Pharma Rare Diseases, we are dedicated to giving our patients improved access to essential treatments. The decision to make AllianceRx Walgreens Prime our exclusive specialty pharmacy and clinical support provider means that our rare disease patients in the US will get improved access to Lysodren® and Metopirone®.”

David Wright, CEO of HRA Pharma, says, “At HRA Pharma we constantly strive to provide accessible and affordable solutions to our patients. I believe making AllianceRx Walgreens the exclusive pharmacy of our Rare Diseases affiliate is a step in the right direction to achieving this goal.”